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Abstract
Background Multiple sclerosis (MS) is a devastating autoimmune disorder characterized by oligodendrocytes (OLGs) loss 
and demyelination. In this study, we have examined the effects of metformin (MET) on the oligodendrogenesis, redox signal-
ing, apoptosis, and glial responses during a self-repairing period (1-week) in the animal model of MS.
Methods For induction of demyelination, C57BL/6 J mice were fed a 0.2% cuprizone (CPZ) for 5 weeks. Thereafter, CPZ 
was removed for 1-week and molecular and behavioral changes were monitored in the presence or absence of MET (50 mg/
kg body weight/day).
Results MET remarkably increased the localization of precursor OLGs  (NG2+/O4+ cells) and subsequently the renewal of 
mature OLGs  (MOG+ cells) in the corpus callosum via AMPK/mammalian target of rapamycin (mTOR) pathway. Moreover, 
we observed a significant elevation in the antioxidant responses, especially in mature OLGs  (MOG+/nuclear factor erythroid 
2-related factor 2  (Nrf2+) cells) after MET intervention. MET also reduced brain apoptosis markers and lessened motor dys-
function in the open-field test. While MET was unable to decrease active astrogliosis (GFAP mRNA), it reduced microgliosis 
by down-regulation of Mac-3 mRNA a marker of pro-inflammatory microglia/macrophages. Molecular modeling studies, 
likewise, confirmed that MET exerts its effects via direct interaction with AMPK.
Conclusions Altogether, our study reveals that MET effectively induces lesion reduction and elevated molecular processes 
that support myelin recovery via direct activation of AMPK and indirect regulation of AMPK/Nrf2/mTOR pathway in OLGs. 
These findings facilitate the development of new therapeutic strategies based on AMPK activation for MS in the near future.
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Introduction
Multiple sclerosis (MS) is a devastating autoimmune 
demyelinating disease of the central nervous system 
(CNS). Lesions in the MS are described by chronic neu-
roinflammation, reactive gliosis and oligodendrocytes 
(OLGs) loss [1]. T lymphocytes are the key players of 
the MS pathobiology, and reactive oxygen spices (ROS) 
have been widely implicated in the adaptive immune 
response through activation of these cells [2]. Interferon-
beta (IFN-β) is the most used first-line intervention in 
relapsing–remitting forms of multiple sclerosis (RRMS) 
and able to modify the course of the disease through mul-
tifactorial mechanism of action (initially act as an immu-
nomodulatory agent in MS) [3]. Recently, activation of 
AMP-activated protein kinase (AMPK) was shown to 
induce signaling downstream of stimulator of interferon 
genes (STING) and promote innate immune signaling 
[4]. Also, it has been shown that AMPK interferes with 
interferon-gamma (IFN-gamma), which activates astro-
cytes/microglia and its activity is decreased in the CNS at 
the onset and exacerbation of experimental autoimmune 
encephalomyelitis (EAE) [5]. Because mitochondrial dys-
function and excessive ROS observed in MS, and oxida-
tive stress is regulated, in part, by, AMPK we postulated 
that metformin (MET)-induced AMPK activation could be 
neuroprotective in our animal model; however, its function 
has yet to be been defined. Among serine/threonine protein 
kinases (STPK), AMPK acts as an energy controller in 
the cell and enrolled in the response to energy imbalance, 
e.g. glucose starvation or ATP depletion [6]. Activation of 
AMPK affects other important members of STPK named 
the mammalian target of rapamycin (mTOR) and conse-
quently reduces the consumption of ATP in addition to 
increased production of it in the cell [7]. Accordingly, acti-
vated AMPK enhances the endothelial function, reduces 
the inflammatory response, and adjusts redox balance 
via regulation of mitochondrial metabolism [8]. Another 
factor that regulates the equilibrium of cellular redox is 
nuclear factor E2-related factor 2 (Nrf2). Nrf2 is a leu-
cine zipper family transcription factor, having an impor-
tant role in the defense of cell against oxidative stress 
[9]. On the other hand, the interaction between AMPK 
and ROS are complex and it has been demonstrated that 
AMPK potentially acts as a downstream target of ROS 
[10]. It was reported that in the endothelial cells, AMPK 
exerts its anti-apoptotic effects through the elimination 
of ROS [11]. It was also shown that the activation of 
AMPK reduced oxidative stress by changing the activity 
or level of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, cyclooxygenase-2 (Cox2), inducible 
nitric oxide synthase (iNOS), or manganese superoxide 
dismutase (SOD) [12]. The underlying mechanisms and 
consequences of AMPK activation in neurodegenerative 
disorders remain mostly uncharacterized. Recently, results 
from the EAE model have shown that supplementation 
with an AMPK activator 5-amino-4-imidazole carboxam-
ide riboside (AICAR) may provide greater efficacy against 
MS [13]. Khan et al. [14] also showed that genetic inac-
tivation of AMPK exacerbates clinical signs in the EAE 
model. Another study showed that during reactive glio-
sis, up-regulated AMPK in activated astrocytes playing 
an important role in the prevention of astrocyte apoptosis 
[15]. Surprisingly, Ajaib et al. have demonstrated that 
AMPK has effects on the survival of oligodendrocytes and 
restore the integrity and function of CNS in EAE model 
[16]. The most commonly used models for studying de 
and remyelination is CPZ, a copper chelating agent, and 
its feeding could induce reversible myelin loss in several 
brain regions, particularly in the corpus callosum (CC) 
[17]. During CPZ treatment blood–brain barrier (BBB) 
is intact and consequently, local injuries happen without 
interfering of autoimmune responses [18]. As MET is able 
to crossing the BBB, for the first time, we have explored 
the effects of MET in the autonomous myelin recovery 
after CPZ challenge. Our data addresses a series of path-
ways involved in the protection ensured by MET to favor 
the viability of OLGs and the preservation of myelin. The 
pathways addressed herein are intertwined and crosstalk to 
apoptosis, oxidative status, autophagy and relevant meta-
bolic pathways that may justify the observed effects under 
MET treatment. In this study, we show the significance of 
MET as a therapeutic factor in the oligodendrogenesis and 
related disorders such as MS.
Materials and methods
Induction of toxic demyelination
7–8 weeks (18–20 g) male C57BL/6 mice were bought from 
Pasteur Institute, Tehran, Iran. Mice were maintained at 
standard temperature (20–22 °C), 12 h light/dark cycle with 
free access to water and food. With 5 weeks consumption 
of 0.2% CPZ mixed into normal rodent chow demyelinat-
ing phenotype was induced in mice. Animal handlings were 
approved by the laboratory animal’s ethic committee, in 
Iran University of Medical Sciences (IUMS) with maximum 
efforts for reducing of animal’s number and their suffering.
Determination of metformin effective dose
To examine which doses of MET is suitable for this study 
mice were intraperitoneal (ip) administered with four 
doses of MET (25, 50, 100, 200 mg/kg/body weight per 
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day dissolved in normal saline) during recovery period and 
average body weight (ABW), and mortality were monitored 
every day. We found that higher doses of MET (100, 200 mg/
kg) considerably decrease ABW of mice and resulting in 
higher mortality. In comparison, 25 and 50 mg/kg of MET 
administration did not significantly affect ABW and mor-
tality than the other doses (data not showed). So, effective 
dose (50 mg/kg/day) selected as an intervention concentra-
tion. This optimized concentration of MET was relatively in 
accordance with previous in vivo studies in different animal 
models [19, 20]. It should mention that usual MET doses 
that are given to adult (70 kg body weight) diabetes type 2 
patients are between 15 mg/kg/day (orally twice a day) and 
37 mg/kg/day (orally in divided doses).
Free and MET recovery periods
Mice randomly divided into four groups (N = 20 per group): 
(1) control group; animals fed normal diet (ND) for 6 weeks 
beside injection (ip) of normal saline (250 µl) as vehicle 
every day in last week, (2) model group; animals fed 0.2% 
CPZ mixed in ND for 5 weeks, and then passed 1-week 
recovery without CPZ besides everyday vehicle injection 
(free recovery period); (3) treatment group; model group 
that received 50 mg MET throughout 1-week recovery (MET 
recovery period); (4) MET control group; control group that 
received 50 mg MET throughout the last 7 days (Fig. 1a).
Behavioral analysis
At the end of experiments, five randomly selected mice 
of each group were evaluated via the open-field test for 
motor impairment analysis. The locomotion of animals in 
the center of the box (50 × 50 cm) was monitored during 
the standard period (5 min) by an overhead camera. Using 
tracking system (EthoVision, Noldus Information Technol-
ogy Co., Wageningen, Netherlands) motor function evalu-
ated through measuring the velocity of movement (cm/s), 
total moved distance (cm), and duration of moved in the 
central zone (s). The ratio of traveled distance in the central 
zone (DC) over the total moved distance (TD) has also been 
calculated (DC/TD) as a sign of anxiety [21].
Tissues preparation and LFB staining
At the end of behavioral assessments, six randomly 
selected mice of each group were euthanized using ip injec-
tion of xylazine (4 mg/kg) and ketamine (50 mg/kg), and 
Fig. 1  Experimental design (a, up) and symbols of relevant groups 
comparison (a, down). Effects of metformin (MET) on behavior 
of mice in the open-field test (b). Data analysis showed that MET 
(50  mg/kg, ip, n = 5) significantly decreased (p < 0.05) anxiety via 
increasing DC/TD ratio (D). Data are presented as means ± SEM, 
analyzed using tow-way ANOVA. *Compared to relevant control 
mice, #compared to free recovery, (*,#p < 0.05; **p < 0.01) with Bon-
ferroni’s correction for multiple comparisons
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transcardially perfused with phosphate buffer saline (PBS, 
pH 7.4) and then with 4% paraformaldehyde dissolved in 
PBS. Brains removed from the skull and post-fixed in 4% 
paraformaldehyde (v/v in PBS) at 4 °C overnight. Afterward, 
brains were rinsed in 30% ice-cold sucrose in PBS. Then 
tissues fixed in the optimal cutting temperature compound 
(OCT, Tissue Tek) and kept in − 80 °C. Later, 5 μm thick-
ness coronal section of each fixed brain were provided and 
distance between 1.58 to 2.30 mm from the bregma was 
selected using mouse brain atlas. In all histological analy-
ses, the rostral part of the CC was used as the target region. 
Moreover, phenotypes of myelin fibers were evaluated via 
staining of some sections with luxol fast blue (LFB) as 
described previously [22].
Transmission electron microscopy (TEM)
After euthanizing mice were transcardially perfused with 4% 
PFA and 2% glutaraldehyde dissolved in 0.1 M cacodylate 
buffer (pH 7.4) respectively. Brains removed from the skull 
and post-fixed in 1% Osmium tetroxide  (OsO4) in 0.1 M PBS 
for 60 min. The brain coronal slices consist of CC region 
were isolated, gently washed in cold 0.1 M PBS, serial 
dehydrated in ethanol and afterward immersed for 15 min 
in 100% acetone, and finally embedded in epoxy resin. Cor-
onal sections contained white matter of CC confirmed by 
toluidine blue staining. The embedded tissues were cut into 
ultrathin sections (0.1 μm), contrasted with aqueous uranyl 
acetate and lead citrate and mounted on copper mesh grids 
(Electron Microscopy Sciences). The ultra-structure of mye-
lin sheaths was observed using a Zeiss EM900 transmission 
electron microscopy (TEM, magnification, × 20,000; Carl 
Zeiss AG, Jena, Germany) at 80 kV. In order to analyze the 
density of myelinated axons, TEM images were imported 
into ImageJ software. Based on the number of myelinated 
axons in the 500 μm2 at × 7000, the density of axons calcu-
lated and thickness of myelin sheath in individual axonal 
fibers measured via calculation of g-ratio (axon diameter/
diameter of axon plus the myelin sheath) from at least 50 
randomly chosen axons per mouse and three mice per group.
Immunofluorescence (IFS) analysis
IFS analyses were performed as described previously [23, 
24]. In brief, the dried sections were rehydrated for 20 min 
in 0.1 M PBS, incubated in blocking solution, and then incu-
bated for 1 h in permeabilization buffer. Prepared sections 
incubated with related primary and secondary antibodies 
dissolved in antibody solution (5% goat serum, 0.05% Triton 
X-100 in PBS). Used primary monoclonal antibodies were: 
mouse anti-neuron glial-2 (NG2, 1:500; bio-rad), and rabbit 
anti-Olig4 (O4, 1:500; bio-rad) as markers of OLGs pro-
genitor cells (OPCs), mouse anti-MOG as marker of mature 
OLGs (1:500; Millipore), rabbit anti-p-AMPK as marker 
of active AMPK (1:500; bio-rad), rabbit anti-p-mTOR as 
marker of autophagy (1:300; Santa Cruz Biotechnology) and 
rabbit anti-p-Nrf2 as marker of antioxidant respond (1:300; 
Santa Cruz Biotechnology). The secondary antibodies were 
FITC conjugated goat anti-mouse IgG for detection of NG2 
and MOG and TR conjugated goat anti-rabbit for detection 
of O4, p-AMPK, p-mTOR and p-Nrf2 (1:1000; Santa Cruz 
Biotechnology). Moreover, for detection of MOG, we also 
used HRP conjugated goat anti-chicken IgY (1:1000; Santa 
Cruz Biotechnology). Counterstaining and visualization of 
a nucleus for IFS sections were performed via DAPI stain-
ing [23, 24].
Monitoring of redox signaling and ADP/ATP ratio
After euthanizing mice were transcardially perfused with 
cold PBS (50 ml) and three brains in each group were rap-
idly removed. Rostral CC and nearby regions were dissected 
in ice and kept at − 80 °C. At the time of experiment, tissue 
was homogenized and centrifuged (3000 rpm for 10 min) 
and then supernatants were used for future assessments. 
Quantity of protein in homogenates was measured by Bicin-
choninic Acid (BCA) protein assay method (Sigma-Aldrich). 
The activity of catalase (CAT), superoxide dismutase 
(SOD), glutathione peroxidase (GPx), as well as the deter-
mination of reactive oxygen species (ROS), lipid peroxida-
tion (TBARS), and total thiol were performed according to 
standard protocols [25–29]. On the other hand, extracellu-
lar ADP/ATP ratio was assessed using ion pair-high perfor-
mance liquid chromatography (IP-HPLC) in the homogenate 
of tree brains in each group [30].
Quantitative reverse transcription PCR (qRT‑PCR)
Total RNA extraction, cDNA synthesis, and qRT-PCR 
were performed as described before [31]. In brief, three CC 
tissues in each group were provided in the same way that 
described in the previous section and then dissected in DEPS 
water and placed at − 80 °C. RNA was isolated according to 
the AccuZol™ (BIONEER) manufacturer’s instructions and 
resolved in 50 µl DEPS water. Then polymerization of cDNA 
was performed using 5 µg RNA as a template by AccuPower 
ready-to-use reverse transcription kit (BIONEER). 1 µg of 
synthesized cDNA used for SYBR Green-based real-time 
PCR via 2X Greenstar qPCP kit (BIONEER). Amplification 
conditions were 95 °C for 10 min (one cycle), 95 °C for 20 s 
(one cycle) and 58 °C for 45 s (one cycle) followed by 95 °C 
for 30 s (40 cycles). Finally, β-actin standards were used for 
sample normalization and by ΔΔCt method relative expres-
sion changes were calculated. The sequences of primer were 
used in this manuscript are shown in Table 1.
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Flow cytometry assessment
Three animals in each group were anesthetized as described 
above, perfused with 50  ml cold PBS and brains were 
quickly detached and hemispheres were separated, freed 
from meninges, placed into ice-cold digestion buffer in 
PBS (DNase I, 1 mg/ml of collagenase D), and cut into 
small pieces and then incubated at 37 °C for 30 min. After 
incubation to stop the enzymatic digestion PBS was added 
and cells passed through a 70 μm nylon cell strainer (Bec-
ton–Dickinson) and centrifuged (2000 rpm, 5 min, 4 °C). 
After aspiration of supernatant, the pellet re-suspended in 
40% and laid on the 70% Percoll solutions (Amersham Phar-
macia Biotech). After centrifuging (2000 rpm, 25 min, room 
temperature) the cells were collected from the interface and 
transferred to a separate tube, washed twice with HBSS con-
taining 10% fetal bovine serum (GibcoBRL) and fixed in 4% 
formaldehyde (20 min in ice). Subsequently, cells incubated 
(45 min, 4 °C) in the mixture of anti-O4 and NG2 primary 
monoclonal antibodies in flow cytometry buffer (FCB). 
After washing, cells incubated (45 min, 4 °C) with second-
ary antibodies. Then, the samples centrifuged (3000 rpm, 
10 min) and cells washed twice and re-suspended in FCB. 
Finally, samples were run on a FACSCalibur Flow Cytom-
eter (BD Biosciences) and evaluated using FlowJo software 
[32].
Western blotting (WB)
Western blot analysis was done as described before [22, 23]. 
In brief, three CC tissues in each group were provided in the 
same way that described in qRT-PCR section and homog-
enized with complete protease inhibitor cocktail (Roche, 
Mannheim, Germany), centrifuged and protein concentra-
tions were estimated by BCA protein assay method (Sigma-
Aldrich). Proteins (50 μg) were resolved on 12.5% SDS-
PAGE gels and via electrophoretic transfer system (Bio-Rad, 
Munchen, Germany) bonds moved to polyvinylidene fluo-
ride (PVDF) membranes. After blocking of membranes 
with 5% milk they incubated (4 °C overnight) with primary 
antibodies (1:500) including rabbit anti-Bax, Bcl-2, cleaved 
caspase-3 and α-tubulin (Santa Cruz Biotechnology). Next 
membranes were carefully washed with PBS-T (PBS, 0.05% 
Tween-20), and incubated (4 °C, 4 h) with horseradish per-
oxidase (HRP) conjugated goat anti-rabbit secondary anti-
bodies (1:1000, Santa Cruz Biotechnology). The blots were 
exposed to DAB (3, 3′-diaminobenzidine and  H2O2) solu-
tion for detection of target antigens. Finally, quantification of 
band intensities was performed by ImageJ software (version 
1.49) after background subtraction and normalization of the 
density of each band to the density of α-tubulin.
In silico analyses
Molecular docking was performed using the AutoDoc4. 
To this end, first the 3-D structures for AMPK, Keep1, 
MTORC1, and MTORC2 proteins were first obtained from 
the RCSB protein database with access codes of 5KQ5, 
DYH2, 5H64 and 5ZCS respectively. The water molecules 
in the structures were manually removed and gastiger partial 
charges were added to atoms by auto-dock tools software. 
Structural sketching and optimization of MET were done 
in Avogadro software, and molecular energy minimization 
conducted using the static algorithm. The partial charges 
of the atoms were calculated and all rotational bands were 
considered as active. Energy maps for involved atom types 
were obtained using the autogrid4 tool, and a 250-run for 
each docking was performed under the Lamarck’s genetic 
algorithm. Output structure images were prepared in VMD 
software.
Statistical analysis
The MET effects on each studied parameter were examined 
using a two-way analysis of variance (ANOVA). For mul-
tiple group comparisons, Bonferroni post hoc test was used 
and the results were considered significant at p < 0.05.
Table 1  Sequence of specific primers used for quantitative real-time 
revers transcription PCR
Gene name Primer sequence
GFAP Forward 5′-AGG TGG AGA GGG ACA ACT TTG-3′
Reverse 5′-TTC ATC TGC CTC CTG TCT ATACG-3′
MOG Forward 5′-CGT CTC TGG AAG AAC AAA GGTC-3′
Reverse 5′-AGA GTA CAT CAT GCC GAC TGC-3′
MAC-3 Forward 5′-GAC ACA CGA TGG AAG CAG TTG-3′
Reverse 5′-AAA TTC ACA GCC CAA GAG ACAG-3′
NG2 Forward 5′-AAT GAG GAC CTG CTA CAC GG-3′
Reverse 5′-CAT CTG TAG TCA ACA GCC GC-3′
Nrf2 Forward 5′-CAT GAT GGA CTT GGA GTT GCC-3′
Reverse 5′-TGT CTT GCC TCC AAA GGA TGTC-3′
Nogo-A Forward 5′-TAC TTA CGT TGG TGC CTT GTTC-3′
Reverse 5′-ATG ATC TAT CTG CGC CTG ATGC-3′
O4 Forward 5′-GAC AGA GAA TGC CTC CCA GA-3′
Reverse 5′-ATC ACT TCC CGC AGA CCA -3′
PLP Forward 5′-AAT TCC CAG CTG ACG GAG ATC ACA -3′
Reverse 5′-TCT ACT CGA AGC CTT GTC AGC ACA -3′
β-actin Forward 5′-TGA AGA TCA AGA TCA TTG CTC CTC -3′
Reverse 5′-TCA GTA ACA GTC CGC CTA GAAG-3′
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Results
Metformin promotes recovery of motor impairment
The general locomotors activity and anxiety were meas-
ured via distance moved and velocity, as well as traveled 
distance in the central zone of the open-field, respectively. 
As predicted, CPZ challenge considerably induced motor 
impairment and even after 1-week free recovery period, 
total traveled distance (p < 0.01), movement velocity 
(p < 0.05), duration traveled in the central zone (p < 0.05) 
and percentage of DC/TD ratio (p < 0.01) were lower com-
pared to control group (Fig. 1b). Metformin administration 
during the 1-week recovery period (MET recovery group) 
notably improved anxiety via increasing DC/TD ratio 
(p < 0.05) compared to the free recovery group (Fig. 1b). 
It is notable that total traveled distance, movement veloc-
ity, duration traveled in the central zone and percentage 
of DC/TD ratio were still significantly (p < 0.05) lower in 
the MET recovery group compared to the relevant control 
group (Fig. 1b).
Fig. 2  Evaluation of effects of metformin (MET) in myelin mark-
ers by IHC of myelin oligodendrocyte glycoprotein (MOG, up pan-
els), luxol fast blue stain (LFB, middle panels) and transitional elec-
tron microscopic (TEM, down panels) in the corpus callosum (CC) 
(a–c). Quantification of all myelin markers show that recovery with 
MET significantly increased remyelination in CC region (p < 0.05, 
a, b). Metformin recovery group exhibited an accelerating effect on 
myelin reconstruction and repair indicating as g-ratio (p < 0.05) in 
TEM analysis (p < 0.05, c). Scale bar = 50  μm. Data are presented 
as mean ± SEM, analyzed using tow-way ANOVA. *Compared 
to relevant control mice, #compared to free recovery, (*,#p < 0.05; 
**p < 0.01; ***p < 0.001) with Bonferroni’s correction for multiple 
comparisons
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Metformin increased myelinating oligodendrocytes 
and decreased microglial activation
Sections from CC region of each brain were stained with 
both LFB which stains the lipid-rich myelin sheath blue, 
and anti-myelin oligodendrocyte glycoprotein (MOG) anti-
body which stains the MOG protein brown (IHC), moreover, 
TEM analysis provided a subjective assessment of the mye-
lin sheath loss in the rostral CC (Fig. 2a–c). As predicted, 
even after 1-week of the free recovery period, the myelin 
level was reduced compared to the control group (Fig. 2a–c). 
MET recovery group had a significant (p < 0.05) positive 
effect on MOG and LFB density compared to the free 
recovery group (Fig. 2a, b). MET recovery group exhibited 
a significant effect on myelin reconstruction and repair indi-
cated in TEM analysis compared to the free recovery group 
(p < 0.05, Fig. 2c). Moreover, using qRT-PCR, the effects 
of MET on mRNA expression of activated microglial (Mac-
3), and astrocytes (GFAP) markers besides myelin proteins 
(MOG and PLP) were tested on CC region of mice after 
1-week recovery (Fig. 3a–d). PCR analysis demonstrated a 
considerable increase in mRNA expression of both myelin 
Fig. 3  Evaluation of effects of metformin (MET) in mRNA expres-
sion of myelin proteins (PLP and MOG) and glial markers (GFAP 
and Mac-3) by q-PCR method in corpus callosum (CC) (a–d). Quan-
tification of results shows that recovery with MET significantly 
increased mRNA expression of PLP (p < 0.05), MOG (p < 0.01) and 
Mac-3 (p < 0.05) but did not any significant effect on GFAP mRNA 
expression in the comparison with free recovery period (p < 0.05, 
a, b). Data are presented as mean ± SEM, analyzed using tow-way 
ANOVA. *Compared to relevant control mice, #compared to free 
recovery, (*,#p < 0.05; **,##p < 0.01) with Bonferroni’s correction for 
multiple comparisons
 N. Sanadgol et al.
1 3
markers PLP (p < 0.05) and MOG (p < 0.01) when recovery 
was accompanied with MET compared to the free recov-
ery group (Fig. 3a, b). As predicted, even after 1-week of 
the free recovery period, the levels of GFAP (p < 0.01) and 
Mac-3 (p < 0.05) mRNA were higher compared to the CPZ 
control group (Fig. 2a–c). Moreover, we observed a signifi-
cant increase in Mac-3 (p < 0.05) but not in GFAP mRNA 
expression in the MET recovery group compared to the free 
recovery group (Fig. 3c, d).
Metformin downregulates apoptotic signaling 
cascades
For the investigation of the apoptosis-related signaling, WB 
analysis was performed for the flagship markers such as Bax/
α-tubulin, Bcl-2/α-tubulin, cleaved caspase-3/α-tubulin and 
Bax/Bcl-2 ratios were measured in all experimental groups 
(Fig. 4a–d). WB results showed persistence of apoptotic sig-
nals even after the 1-week free recovery period compared to 
the CPZ control group (p < 0.05, Fig. 4b, d). Administration 
of MET during the 7 days of recovery period had a signifi-
cant protective effect by increasing Bcl-2/α-tubulin ratio in 
comparison with the free recovery group (Fig. 4a). Notably, 
MET exerted its protective effect through intensive elevation 
of anti-apoptotic protein Bcl-2 level instead of decreasing 
apoptotic protein Bax level (Fig. 4b). Recovery with MET 
significantly decreased the Bax/Bcl-2 ratio (p < 0.05), in 
comparison with the free recovery group (Fig. 4c). Alterna-
tively, administrating MET during recovery period reduced 
cleaved caspase-3/α-tubulin ratio indicating apoptosis reduc-
tion (p < 0.05, Fig. 4d).
Metformin increased recruitment 
of oligodendrocytes precursor cells
To study the intrinsic myelin regeneration capacity (recruit-
ment of OPCs), flow cytometry, immunostaining and qRT-
PCR assays for the O4 (late-stage) and NG-2 (early-stage) 
OPCs markers were performed in all experimental groups. 
Flow cytometry for O4 and NG-2 (in vivo analysis) indi-
cated that both were expressed with different patterns in all 
experimental groups (Fig. 5a). In the free recovery group, 
there was a slight increase (from 2.19 to 4.51%) in the papu-
lation of NG-2+/O4+ double-positive cells (represent OPCs 
in the transition-stage) in the CC compared to the CPZ con-
trol group (Fig. 5a). But in MET recovery group, NG-2+/
O4+ populations was increased by 10.79% compared to the 
free recovery group (Fig. 5a). MET treatment dramatically 
Fig. 4  Evaluation of effects of metformin (MET) in protein expres-
sion of apoptosis markers (Bax, Bcl-2, and cleaved Caspase-3) by 
WB method in corpus callosum (CC) (a–d). Quantification of results 
show that recovery with MET significantly decreased Bax/Bcl-2 
ratio (c, p < 0.05), and cleaved caspase-3/α-tubulin ratio (d, p < 0.05) 
in the comparison with free recovery period. Data are presented as 
mean ± SEM, analyzed using tow-way ANOVA. *Compared to rele-
vant control mice, #compared to free recovery, (*,#p < 0.05) with Bon-
ferroni’s correction for multiple comparisons
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Fig. 5  Evaluation of effects of metformin (MET) in OLGs population 
(O4 and NG2) in corpus callosum (CC) (a–d). Flow cytometery with 
double staining of O4 and NG2 showed both markers were expressed 
in control and the recovery groups (a). In free recovery group, there 
was a minor increase (from 2.19 to 4.51%) in  O4+/NG-2+ double-
positive OPCs (transition-stage) in the CC compared to the control 
group (a). In MET recovery group,  O4+/NG-2+ population increased 
by 10.79% compared to the free recovery group (a). One-week recov-
ery with MET increased NG-2+ cells population by 4.94% in contrast 
to the free recovery group (a). Moreover, in MET recovery group O4 
population only increased by 0.15% in contrast to the free recovery 
group (a). IHC of coronal sections through the CC for NG2 (green), 
O4 (red) and DAPI nuclear stain (blue) for in situ analysis of OPCs 
were performed (Fig.  4b, c). NG2 and O4 double-staining shows 
increased immunoreactivity after 1-week recovery period with MET 
in comparison with free recovery period (b, c). In addition, previous 
data have been confirmed by q-PCR analysis of NG2 and O4 mRNA 
expression in CC (3D). Expression of Nogo-A as negative control-
ler of remyelination has been significantly decreased during MET 
recovery period in comparison with free recovery period (d). Scale 
bar = 50 μm. Data are presented as mean ± SEM, analyzed using tow-
way ANOVA. *Compared to relevant control mice, #compared to free 
recovery, (*,#p < 0.05; **p < 0.01; ***p < 0.001) with Bonferroni’s 
correction for multiple comparisons
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increased NG-2+ population (NG-2+/O4− represent a unique 
type of glial cell) by 4.94% in contrast to the free recov-
ery group (Fig. 5a). Moreover, in MET recovery group, O4 
population (NG-2−/O4+ represent a premature OLGs cell) 
was increased only by 0.15% in contrast to the free recovery 
group (Fig. 5a). IHC double staining for O4 and NG-2 (in 
situ analysis) confirmed previous findings and both markers 
were significantly overexpressed in the MET recovery group 
in contrast to the free recovery group (Fig. 5b, c). Indeed, 
MET treatment significantly increased the numbers of O4 
(p < 0.05) and NG-2 (p < 0.05) positive cells in CC compared 
to the free recovery group (Fig. 5b, c). Furthermore, qRT-
PCR also showed a significant increase in O4 (p < 0.05) and 
NG-2 (p < 0.05) mRNA expression and decrease in Nogo-
A (negative controller of myelination) mRNA expression 
(p < 0.05) in the MET recovery group compared to the free 
recovery group (Fig. 5d).
Metformin induced activation AMPK 
and inactivation of mTOR in oligodendrocytes
Double-staining of cells with mature oligodendrocyte 
marker (MOG) beside either mTOR or AMPK were carried 
out to localize active form of following markers (p-AMPK 
and p-mTOR) in CC region (Fig. 6a, b). Double-staining of 
cells with MOG and p-mTOR showed that population of 
 MOG+ cells was not altered by MET treatment but it signifi-
cantly declined p-mTOR and these mice did not exhibit sig-
nificant changes in  MOG+/p-mTOR+ double-positive cells 
compared to control group (Fig. 6a). Recovery by MET sig-
nificantly increased the numbers of  MOG+ cells (p < 0.05) 
and decreased p-mTOR+ cells (p < 0.05) but slightly 
decreased  MOG+/p-mTOR+ double-positive cells in CC 
compared to the free recovery group (Fig. 6a). On the other 
hand, double-stained MOG with p-AMPK indicated that 
MET considerably increased (p < 0.01) p-AMPK, but had 
no substantial effect on the population of  MOG+/p-AMPK+ 
double-positive cells compared to the control mice that were 
not treated by MET (Fig. 6b). However, MET recovery nota-
bly increased the numbers of both p-AMPK+ cells (p < 0.05) 
and  MOG+/p-AMPK+ double-positive cells (p < 0.05) in CC 
compared to the free recovery group (Fig. 6b).
Metformin induced activation of Nrf2 
in oligodendrocytes
Double-staining of mature OLGs marker (MOG) besides 
p-Nrf2 was done to localize the active form of Nrf2 
Fig. 6  Evaluation of effects of metformin (MET) in m-TOR and 
AMPK activation in mature OLGs (a, b). IHC of coronal sections 
through the CC showing labelling with a monoclonal antibody that 
is specific to MOG (green), p-AMPK (red) and p-mTOR (red), along 
with DAPI nuclear stain (blue) (a, b). p-mTOR staining shows signif-
icantly decreased in immunoreactivity after 1-week recovery period 
with MET in comparison with free recovery period (p < 0.05, a). 
p-AMPK staining shows significantly increased in immunoreactiv-
ity after 1-week recovery period with MET in comparison with free 
recovery period (p < 0.05, b). Scale bar = 50 μm. Data are presented 
as mean ± SEM, analyzed using tow-way ANOVA. *Compared 
to relevant control mice, #compared to free recovery, (*,#p < 0.05; 
**p < 0.01) with Bonferroni’s correction for multiple comparisons
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(p-Nrf2) in CC region (Fig. 7a, b). IHC stained MOG 
and p-Nrf2 indicated that MET did not significantly affect 
either  MOG+, p-Nrf2+ and  MOG+/p-Nrf2+ double-posi-
tive cells in the control mice compared to the control mice 
that were not treated by MET (Fig. 7a, b). Double-stain-
ing of cells with an anti-MOG and anti-p-Nrf2 antibodies 
indicated that recovery with MET remarkably increased 
the numbers of  MOG+, p-Nrf2+ and  MOG+/p-Nrf2+ cells 
in CC compared to the free recovery group (Fig. 7a, b). 
Also by qRT-PCR analysis, we observed a significant 
increase in Nrf2 mRNA expression in MET recovery 
group compared to the free recovery group (p < 0.05, 
Fig. 7c).
Effects of metformin on redox signals and ADP/ATP 
ratio
Antioxidant index
Effects of MET on antioxidant indexes were measured 
in all experimental groups. Antioxidant indexes; namely 
CAT, SOD and GPx were significantly decreased after 
5 weeks of CPZ treatment in comparison with mice fed 
with normal chow (data not shown). On the other hand, 
CAT (p < 0.01), SOD (p < 0.01) and GPx (p < 0.05) were 
significantly increased after 1-week free recovery period 
in comparison with mice fed with the normal chow 
Fig. 7  Evaluation of effects of metformin (MET) in Nrf2 activation in 
mature OLGs (a–c). IHC of coronal sections through the CC showing 
labelling with a monoclonal antibody that is specific to MOG (green), 
p-Nrf2 (Red), along with DAPI nuclear stain (blue) (a). p-Nrf2 stain-
ing shows significantly increased in immunoreactivity after 1-week 
recovery period with MET in comparison with free recovery period 
(p < 0.05, a). In addition, this observation has been confirmed 
by q-PCR analysis of Nrf2 mRNA expression in CC (c). Expres-
sion of Nrf2 has been significantly increased during MET recovery 
period in comparison with free recovery period (p < 0.05, b). Scale 
bar = 50 μm. Data are presented as mean ± SEM, analyzed using tow-
way ANOVA. *Compared to relevant control mice, #compared to free 
recovery, (*,#p < 0.05; **p < 0.01) with Bonferroni’s correction for 
multiple comparisons
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(Fig.  8a–c). Administration of MET during recovery 
period, had an undeniable protective effect by increas-
ing CAT (p < 0.01), SOD (p < 0.05) and GPx (p < 0.05) 
indexes in comparison with the free recovery group 
(Fig. 8a–c). Metformin administration in control mice 
did not have a significant effect on the concentration of 
catalase, SOD, and glutathione in comparison with mice 
receiving vehicle (Fig. 8a–c).
Oxidant index
Effects of MET on oxidant indexes in coronal slices in 
CC were measured in all experimental groups. Oxidant 
indexes; namely ROS, Thiol and TBARS were significantly 
increased after 5 weeks of CPZ treatment in comparison 
with mice fed with the normal chow (data not shown). 
On the other hand, ROS (p < 0.01), Thiol (p < 0.001) and 
Fig. 8  Effects of metformin (MET) on oxidant and antioxidant 
indexes in coronal slices in corpus callosum (CC). Oxidant index; 
reactive oxygen spices (ROS), Thiol and TBARS were significantly 
decreased after recovery with MET in comparison with free recov-
ery period (p < 0.05). Antioxidant index; catalase (CAT), superoxide 
dismutase (SOD) and glutathione (GPx) were significantly increased 
after recovery with MET in comparison with free recovery period 
(p < 0.01, p < 0.05 and p < 0.05 respectively). ADP/ATP level was sig-
nificantly increased after recovery with MET in comparison with free 
recovery period (p < 0.05). Data are presented as mean ± SEM, ana-
lyzed using tow-way ANOVA. *Compared to relevant control mice, 
#compared to free recovery, (*,#p < 0.05; **,##p < 0.01; ***p < 0.001) 
with Bonferroni’s correction for multiple comparisons
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TBARS (p < 0.01) were significantly increased after 1-week 
free recovery period in comparison with mice fed with the 
normal chow (Fig. 8d–f). Administration of MET during the 
7 days of recovery period had a significant protective effect 
by decreasing ROS (p < 0.05), Thiol (p < 0.05) and TBARS 
(p < 0.05) indexes in comparison with the free recovery 
group (Fig. 8d–f). Metformin administration in the control 
mice did not have a significant effect on the concentration of 
ROS, Thiol and TBARS in comparison with mice receiving 
vehicle (Fig. 8d–f).
ADP/ATP ratio
Extracellular ADP/ATP ratio was remarkably decreased 
after 5 weeks of CPZ treatment in comparison with mice fed 
with the normal chow (data not shown). On the other hand, 
extracellular ADP/ATP ratio was remarkably increased 
(p < 0.01) after 1-week free recovery period in comparison 
with mice fed with the normal chow (Fig. 8g). Administra-
tion of MET during the 7 days of recovery period increased 
extracellular ADP/ATP ratio (p < 0.05) in comparison with 
the free recovery group (Fig. 8g). Remarkably, MET admin-
istration in control mice increased extracellular ADP/ATP 
ratio (p < 0.05) in comparison with mice receiving vehicle 
(Fig. 8g).
Molecular modeling
Molecular modeling techniques were used to understand the 
atomic details of the molecular mechanism of interaction 
between MET and AMPK in comparison with other proteins 
involved in the energy regulation pathway, including Nrf2-
Keep1, MTORC1 and MTORC2. The obtained results are in 
agreement with experimental data and confirm the specific 
activity effects of MET on AMPK. On the one hand, the 
interaction of MET with other proteins shows a weak and 
unstable connection that can be indicative of the ineffective-
ness, or the insignificant and inadequate effects of the MET 
on other pathways. On the other hand, the interaction site 
of MET on the AMPK molecule is entirely consistent with 
the location and mode of interaction of its main activator, 
AMP, which, in accordance with the experimental results, 
indicated its positive effects through the direct increase of 
AMPK activation (Fig. 9 and Table 2).
Discussion
In this manuscript, we have studied diabetes medication, 
metformin (MET), for myelin repair during post-demyeli-
nation recovery (regeneration/remyelination) period in the 
CPZ model of toxic demyelination after CPZ cessation. 
Fig. 9  Docking studies of 
metformin on AMPK. Crystal 
structure of AMPK-metformin 
docked complex
Table 2  Docking results of metformin interaction with target proteins
Molecule ∆G bonding affinity (Kcal/
mol)
Number 
in cluster
AMPK − 6.3 128
Keep1 − 4.1 110
MTORC1 − 3.8 135
MTORC2 − 4.3 98
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CPZ-induced myelin loss after 5  weeks and this acute 
demyelination could be endogenously repaired after an 
appropriate recovery period and CPZ cessation. Therefore, 
this model is similar to the sign of the pathophysiology of 
primary progressive MS and to a lesser extent progressive 
relapsing MS with the exception that in human subjects 
endogenous repair occurred gradually [33]. Moreover, CPZ 
induced the OLGs dystrophy equivalent to what happened 
in MS lesions (type III) [34].
AMPK/mTOR pathway is one of the important regula-
tors of the cellular metabolism that is activated during stress 
conditions and depletion of ATP in the cell. AMPK inhi-
bition leading to hindering of autophagy and attenuation 
of astrocytes viability in the case of oxygen and glucose 
deprivation [35]. Under the stress situations, AMPK inhib-
its processes that utilize energy and activates the catabolic 
pathways inside the cell. Moreover, mTOR is essential for 
controlling many pathways, such as cell growth, autophagy, 
insulin signaling, and transport of nutrients to cell [35]. On 
the other hand, due to the interaction between the metabo-
lism and redox state, it is proposed that Nrf2 and AMPK 
may cooperate in exerting of MET protective effects.
We exhibited that MET-mediated AMPK activation 
could accelerate myelin recovery and improve behavioral 
dysfunctions. Here, we examined whether these effects are 
exerted through cross-talk between AMPK/Nrf2/mTOR 
axis or other signaling pathways are involved. Increas-
ing of Nrf2 expression in OLGs confirmed that MET was 
involved in the control of the redox status in these cells 
through either AMPK activation or mTOR inactivation. In 
our study, administration of MET significantly improved 
motor impairment and decreased anxiety, which was mani-
fested by an increase in oligodendrogenesis accompanied 
by decreased apoptosis signaling. The reduced behavioral 
dysfunctions and promoted neurogenesis might be due to 
the activation of protein kinase C-CREB binding protein 
(PKC-CBP) pathway [36]. Apparently, OLGs apoptosis is a 
vital feature in the pathogenesis of MS and caspase-medi-
ated death of OLGs is critical for demyelination [37]. Our 
study showed that MET-induced AMPK activation is able to 
control brain apoptosis by decreasing cleaved caspase-3 and 
increasing  Bcl2 protein levels. Growing evidence suggests 
that AMPK/mTOR pathway may participate in neuroinflam-
mation, neurodegeneration and protection of neurons from 
apoptosis through enhancing neuronal autophagy [38–41]. 
MET-induced mTOR inhibition could maintain the levels of 
ATP in OLGs, specifically when oxidative phosphorylation 
is impaired after redox imbalance [42, 43]. Several stud-
ies have shown that oxidative damage of OLGs and axonal 
dystrophy occurred in initial phases of active MS lesions 
and oxidative stress also impairs OPCs differentiation by 
epigenetic mechanisms such as histone acetylation [44–46]. 
In this regard, our study showed that MET prevents brain 
apoptosis and even promotes endogenous myelin repair via 
migration of OPCs to the lesion site.
It has been shown that AMPK signaling attenuated ROS 
generation by reduction of activity of NADPH oxidase, and 
MDA levels accompanied by overexpression of SOD [16, 
47]. A detoxifying factor Nrf2 has an important role in the 
protection of the cells from oxidative stress via binding to 
the cis-acting element called the antioxidant responsive ele-
ment (ARE) [48–50]. Nrf2 knockdown inhibits the cell pro-
liferation and it also reduces the intracellular ATP level [51]. 
Our study confirms that AMPK activation is exquisitely cou-
pled to mitochondrial metabolism through the increase of 
the cellular ADP/ATP ratio. This may be moderately due to 
identified effects of MET on the disruption of ROS, Thiol 
and TBARS production or induction of CAT, SOD, and GPx 
production.
It is also shown that antioxidant response proteins like 
Nrf2 are elevated in MS lesions and Nrf2 activation induced 
by AMPK is believed to have a key role in the pathogenesis 
of various diseases including pathogenic and neurodegen-
erative disorders [52, 53]. On the other hand, the reduc-
tion of Nrf2 caused activation of AMPK and inhibition of 
the mTOR pathway and loss of function mutation in Nrf2 
resulted in the mTOR activation [52, 54]. Ashabi et al. [55] 
indicated that pretreatment by MET protects hippocampal 
neurons via increasing Nrf2 antioxidant pathway in cerebral 
ischemia. We propose that under CPZ-induced oxidative 
stress, MET enhances Nrf2-mediated antioxidant response 
in OLGs and activation of the related enzymes, thus, pav-
ing a way for a permissive environment for recruitment and 
maturation of OPCs.
An extensive population of OLGs lineage exists within 
the adult CNS, but do not express proteins such as myelin 
basic protein (MBP) and 2, 3-cyclic nucleotide 3-phospho-
diesterase (CNP) as a mature OLGs markers. Instead, these 
cells have phenotypic characteristics of a more immature 
stage of the OLGs lineage. They express the platelet-derived 
growth factor α-receptor (PDGFRα), in addition to O4 and 
the NG2, all widely accepted as markers for OPCs through-
out development. However,  NG2+ cells residing in the adult 
CNS do not resemble embryonic or neonatal  NG2+ cells in 
terms of their morphology or proliferation characteristics, 
but instead represent a unique type of glial cell that has the 
ability to react rapidly to CNS damage [56, 57].
Remarkably, MET treatment dramatically increased 
NG-2+/O4− population of glial cell and decreased MAC-3 
mRNA expression on the lesion site. This function could 
be resulting in the repopulation of the beneficial glial cell 
instead of harmful and inflammatory cells in an unidentified 
pathway.
It has been shown that A2B5/PDGFRα double-positive 
cells are the main population during early progenitor stage 
of OPCs differentiation. In the late progenitor stage, A2B5/
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PDGFRα was disappeared and O4 marker was observed. 
In the premyelinating OLGs, the expression of NG2 was 
increased, while the expression of O4 decreased compared to 
the previous stage. Finally, the myelinating OLGs expressed 
less NG2, which were highly positive for MOG, a major 
protein involved in the myelination process [32]. In accord-
ance with these expression patterns, our study confirmed 
that MET significantly promoted the recruitment of inter-
mediate  (NG2+O4+) and premature  (NG2−O4+) OPCs to 
lesion site probably through regulation of AMPK/Nrf2 path-
way. Molecular modeling studies similarly confirmed the 
experimental results indicating that MET has an effective 
interaction with AMPK and ineffective interface with both 
Nrf2 and mTOR. It is predicted that the protective effect of 
MET on an abundance of OLGs and remyelination are not 
limited to CC and it is recapitulated in other CNS regions, 
as a consequence of CPZ challenge.
On the other hand, Nogo-A protein, a potent inhibitor of 
neurite growth, is the member of the reticulon proteins and 
exert several functions such as the regulation of growth and 
synaptic plasticity in the CNS [58]. It has been reported that 
silencing Nogo-A promotes functional recovery in demy-
elinating disease [59]. In this study, the recovery along 
with metformin significantly decreased the expression of 
Nogo-A mRNA. Our previous finding indicated that con-
sumption of metformin during recovery period potentially 
induced p-AMPK and promoted repopulation of mature 
OLGs through up-regulation of neurotropic factors as well 
as recruitment of  Olig2+ precursor cells [60]. In accord-
ance with our results, Largani and their colleagues recently 
showed that co-administration of CPZ and MET (oral gavage 
of 100 mg/kg) for 6 weeks improved mitochondrial hemo-
stasis and increased myelinated axons via upregulating the 
expression of mitochondrial biogenesis genes and amelio-
rating the astrogliosis, microgliosis and oxidative stress 
induced by CPZ [61]. We should mention that this group 
only focused on the prophylactic effect (with co-adminis-
tration with CPZ) of MET but not its therapeutic effects 
(administration after CPZ cessation).
Taken together, we observed that MET-induced AMPK 
activation triggers cell and molecular mechanisms that 
accelerate oligodendrogenesis and improves behavioral 
deficits during the 1-week recovery period (Fig. 10). This 
study showed the corporation of the energy sensitive sign-
aling (AMPK/mTOR) and redox signaling (Nrf2) for the 
elevation of OLGs regeneration and myelin repair after acute 
demyelination.
Conclusion
Altogether, we conclude that MET induced myelin regenera-
tion by increasing the number of OPCs  (NG2+/O4+ cells) 
and regulation of mTOR/AMPK signaling pathway. Further, 
Fig. 10  Schematic description of the cell and molecular effects of metformin on myelin repair during recovery period after acute cuprizone-
induced demyelination
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MET also stimulates Nrf2-related antioxidant pathway, and 
therefore prevents apoptosis and moderates acute gliosis 
and ultimately provides a suitable condition for endogenous 
myelin renovation. Undoubtedly, further studies are neces-
sary to determine whether pharmacological or genetic inhi-
bition of AMPK phosphorylation prevents the MET neuro-
protective effects, and to justify the reliance of p-AMPK as 
the key player in similar conditions. To date, this is the first 
study that provides a shared of objective evidence for the 
description of MET-enhanced remyelination via adjustment 
of AMPK/Nrf2/mTOR signaling in CNS.
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